{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:50Z","timestamp":1790758730126,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","award":["PHRC 2004"],"award-info":[{"award-number":["PHRC 2004"]}],"id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0168834","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T21:33:29Z","timestamp":1483997609000},"page":"e0168834","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis"],"prefix":"10.1371","volume":"12","author":[{"given":"Bruno","family":"Brochet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde S. A.","family":"Deloire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9","family":"Loock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Baschet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Debouverie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pittion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ouallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clavelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PROMESS study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.57.11.1969","article-title":"Final analysis of the European multicenter trial on IFN_-1b in secondary-progressive MS","volume":"57","author":"L Kappos","year":"2001","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/01.WNL.0000145561.08973.4F","article-title":"Interferon beta-1b in secondary progressive MS A combined analysis of the two trials","volume":"63","author":"L Kappos","year":"2004","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon beta-1a in secondary progressive MS. Clinical results","volume":"56","year":"2001","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of interferon \u03b2-1a on MSFC progression in secondary progressive MS","volume":"59","author":"JA Cohen","year":"2002","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"K Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"Supp.16","key":"ref7","doi-asserted-by":"crossref","first-page":"S49.001","DOI":"10.1212\/WNL.86.16_supplement.S49.001","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the Phase III double-blind, placebo-controlled ORATORIO study","volume":"86","author":"X Montalban","year":"2016","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"F Lublin","year":"2016","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"BD Trapp","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"A Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"R Magliozzi","year":"2007","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"JM Frischer","year":"2009","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40263-016-0340-9","article-title":"Secondary Progressive Multiple Sclerosis: Definition and Measurement","volume":"30","author":"D Plantone","year":"2016","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progression of neurological impairment in patients with chronic progressive multiple sclerosis","volume":"37","author":"DE Goodkin","year":"1995","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial","volume":"360","author":"HP Hartung","year":"2002","journal-title":"Lancet"},{"key":"ref16","first-page":"345","article-title":"Multiple sclerosis and the autoimmunization process. Treatment by antimitotics","volume":"215","author":"G Aimard","year":"1966"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunesuppression in progressive multiple sclerosis A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"SL Hauser","year":"1983","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","article-title":"Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study","volume":"54","author":"W Likosky","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","year":"1991","journal-title":"Lancet"},{"key":"ref20","first-page":"910","article-title":"Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group","volume":"43","author":"HL Weiner","year":"1993"},{"key":"ref21","first-page":"73","article-title":"Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients","volume":"218","author":"H Zephir","year":"2004"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.51.1.239","article-title":"A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis","volume":"51","author":"DE Goodkin","year":"1998","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"WI McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"FD Lublin","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 4","key":"ref25","first-page":"S173","article-title":"Assessing incapacity at early stages of Multiple sclerosis using the EDSS","volume":"165","author":"B Brochet","year":"2009","journal-title":"Rev Neurol (Paris)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorials in biostatistics: competing risks and multistate models","volume":"26","author":"H Putter","year":"2007","journal-title":"Statist Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i08","article-title":"Multistate Models for Panel Data: The msm Package for R","volume":"38","author":"CH Jackson","year":"2011","journal-title":"J Stat Softw"},{"key":"ref28","unstructured":"Touraine C, Joly P, Gerds TA. SmoothHazard: Fitting illness-death model for interval-censored data. R package version 1.0.9. 2013; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/CRAN.R-project.org\/package=SmoothHazard\" xlink:type=\"simple\">http:\/\/CRAN.R-project.org\/package=SmoothHazard<\/ext-link>."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"DR Cox","year":"1972","journal-title":"J Royal Statistical Society"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis","volume":"85","author":"A Scalfari","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"D P\u00f6hlau","year":"2007","journal-title":"Mult Scler"},{"key":"ref32","first-page":"967","article-title":"Immunodepressive therapy in neurology","volume":"75","author":"PF Girard","year":"1967","journal-title":"Presse Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0303-8467(75)80007-2","article-title":"Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone","volume":"78","author":"OR Hommes","year":"1975","journal-title":"Clin Neurol Neurosurg"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"J Chataway","year":"2014","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0022-5347(01)63185-9","article-title":"Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide","volume":"159","author":"D De Ridder","year":"1998","journal-title":"J Urol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458507083625","article-title":"Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis","volume":"14","author":"C Lebrun","year":"2008","journal-title":"Mult Scler"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2016.01.015","article-title":"Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group\/2009-02 study","volume":"58","author":"A Llombart-Cussac","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458511398371","article-title":"Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study","volume":"17","author":"E Le Page","year":"2011","journal-title":"Mult Scler"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/jnnp.62.3.282","article-title":"Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor","volume":"62","author":"GP Rice","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458515605908","article-title":"Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis","volume":"22","author":"R Ratzer","year":"2016","journal-title":"Mult Scler"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0168834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:30:17Z","timestamp":1749875417000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0168834"}},"subtitle":[],"editor":[{"given":"Tim","family":"Friede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0168834","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]}}}